DISCOVER OUR PIONEERING CONTRIBUTIONS TO ONCOLOGY THROUGH PRESTIGIOUS JOURNALS AND PLATFORMS LIKE ASCO, ESMO, AND SABCS. ELEVATE YOUR INSIGHTS WITH OUR CUTTING-EDGE CLINICAL TRIAL PUBLICATIONS.
EMPOWERING PROGRESS: ONCOLOGY CLINICAL TRIALS SPOTLIGHT
PUBLICATIONS
THE ULTIMATE GOAL OF MEDSIR PROJECTS IS THE PUBLICATION OF ITS STUDY RESULTS, WHETHER IN PEER-REVIEWED JOURNALS OR AT A NUMBER OF NATIONAL AND INTERNATIONAL CONFERENCES IN THE FORM OF ABSTRACTS, POSTERS, OR ORAL PRESENTATIONS.
STUDY
OFFICIAL TITLE
DISEASE
JOURNAL/
CONGRESS
YEAR
DOWNLOAD
ATRACTIB
Atezolizumab plus paclitaxel and bevacizumab as first-line treatment 1 of advanced triple-negative breast cancer: the ATRACTIB phase 2 trial
Breast
Nature Medicine
2025
TUXEDO-3
Patritumab deruxtecan (HER3-DXd) in active brain metastases (BM) from metastatic breast (mBC) and non–small cell lung cancers (aNSCLC), and leptomeningeal disease (LMD) from advanced solid tumors: results from the TUXEDO-3 phase II trial
BREAST, LUNG AND LMS
ASCO
2025
PARSIFAL LONG
Extended follow-up of palbociclib with fulvestrant or letrozole for endocrine-sensitive, hormone receptor-positive/HER2-negative advanced breast cancer in the PARSIFAL trial
Breast
ESMO Open
2025
PALMIRA
Second-Line Endocrine Therapy With or Without Palbociclib Rechallenge in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: PALMIRA Trial
BREAST
(Journal) Journal of Clinical Oncology
2025
ADELA
Double-blind, Placebo-controlled, Randomized Phase 3 Trial of Elacestrant (ELA) + Everolimus (EVE) Versus ELA + Placebo (PBO) in ER+/HER2- Advanced Breast Cancer (aBC) Patients (pts) with ESR1-mutated Tumors Progressing on Endocrine Therapy (ET) + CDK4/6i
BREAST
ASCO
2025
LUPER
Lurbinectedin plus pembrolizumab in relapsed small cell lung cancer (SCLC): the phase I/II LUPER study
Lung
Journal of Thoracic Oncology
2025
TUXEDO-3 (cohort 3)
Patritumab deruxtecan (HER3-DXd) in leptomeningeal metastatic disease of solid tumors: results from a prospective phase II trial
Leptomeningeal disease from any solid tumor
Nature Medicine
2025
TRANSFAL
Biomarkers of palbociclib response in hormone receptor-positive advanced breast cancer from the PARSIFAL trial
Breast
NPJ Breast
2025
TUXEDO-4
TUXEDO-4: Phase II study of trastuzumab-deruxtecan in HER2-low breast cancer with new or progressing brain metastases
Breast
Future Oncology
2025
CT1/T2CN0 PHERGAIN substudy
Clinical outcomes in patients (pts) with stage cT1/T2cN0 HER2[+] breast cancer (BC) treated with neoadjuvant trastuzumab and pertuzumab (HP): An exploratory analysis from the PHERGain trial
Breast
ESMO Breast
2025
PRIMED
Prevention of sacituzumab govitecan-related neutropenia and diarrhea in patients with HER2-negative 3 advanced breast cancer (PRIMED): an open-label, single-arm, phase 2 trial
Breast
eClinicalMedicine
2025
ADELA
TPS 43 - ADELA: A Double-Blind, Placebo-Controlled, Randomized Phase 3 Trial of Elacestrant + Everolimus vs Elacestrant + Placebo in ER+/HER2– Advanced Breast Cancer Patients With ESR1-Mutated Tumors Progressing on Endocrine Therapy
Breast
MBCC 2025
2025
Other MEDSIR related articles
